

Remarks

Currently Claims 1-23 are pending.


The specification has been amended to recite the claim of priority and to include an abstract on a separate page.

Claims 3-8 and 10-11 are amended herein. Claim 3 is amended to place the claim in independent form and to remove a repeated word. Claims 4-8 and 10 are amended to remove multiple dependencies for the purpose of reducing claim fees. Claims 8 and 10 are further amended and to remove redundant phrases. Claim 10 is further amended to rewrite "human" as new claim 12. Claim 11 is amended to recite additional specific conditions. The foregoing amendments do not narrow the scope of the claims and are not made for purposes of patentability. No new matter is added.

New claims 12-23 are added. Support for these claims may be found throughout Applicants' specification including the original claims, pages 19, lines 24-28 and examples 34 and 247. No new matter is added.

Applicant respectfully submits that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is invited to contact the undersigned at 919 483-8222, to discuss this case further if desired.

Respectfully submitted,



Lorie Ann Morgan  
Attorney for Applicants  
Registration No. 38,181

Date: 8 February, 2005  
GlaxoSmithKline  
Five Moore Drive, PO Box 13398  
Research Triangle Park  
North Carolina 27709  
(919) 483-8222  
fax: (919) 483-7988